EP1894940A1 - TNF superfamily fusion proteins - Google Patents
TNF superfamily fusion proteins Download PDFInfo
- Publication number
- EP1894940A1 EP1894940A1 EP06017891A EP06017891A EP1894940A1 EP 1894940 A1 EP1894940 A1 EP 1894940A1 EP 06017891 A EP06017891 A EP 06017891A EP 06017891 A EP06017891 A EP 06017891A EP 1894940 A1 EP1894940 A1 EP 1894940A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fusion protein
- component
- nucleic acid
- iii
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Definitions
- the present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein.
- TNFSF TNF superfamily
- the fusion protein is present as a trimeric complex or as an oligomer thereof and is suitable for therapeutic, diagnostic and/or research applications.
- TNFSF cytokines e.g. the CD95 ligand (CD95L) is required for efficient receptor binding and activation.
- TNFSF cytokines e.g. the CD95 ligand (CD95L)
- CD95L CD95 ligand
- Trimeric complexes of TNF superfamily cytokines are difficult to prepare from recombinant monomeric units.
- WO 01/49866 and WO 02/09055 disclose recombinant fusion proteins comprising a TNF cytokine and a multimerization component, particularly a protein from the C1 q protein family or a collectin.
- a disadvantage of these fusion proteins is, however, that the trimerization domain usually has a large molecular weight and/or that the trimerization is rather inefficient.
- the present invention relates to a fusion protein comprising
- the fusion protein may be a monomeric protein or a multimeric protein.
- the fusion protein is present as a trimeric complex consisting of three monomeric units which may be identical or different.
- a trimeric complex consists of three identical fusion proteins.
- the trimeric complex shows biological activity. It was found, however, that oligomers of the trimeric complex, e.g. defined complexes wherein the basic trimeric structure is present 2, 3 or 4 times, also have biological activity.
- Component (i) of the fusion protein is a cytokine of the TNF superfamily or a receptor binding domain thereof.
- component (i) is a mammalian, particularly human cytokine or a receptor binding domain thereof including allelic variants and/or derivatives thereof.
- the TNF cytokine is a receptor binding domain thereof capable of binding to the corresponding cytokine receptor and preferably capable of receptor activation, whereby apoptotic or proliferative activity may be caused.
- the cytokine may e.g. be selected from TNF superfamily members, e.g.
- human TNFSF-1 to -18 as indicated in Table 1, preferably from CD95L (FasL), TRAIL, TNF ⁇ , LTB, CD40L, CD30L, OX40L, RANKL, TWEAK, Lta, Ltab2, LIGHT, CD27L, 41-BB, GITRL, APRIL, EDA, VEGI and BAFF or a receptor binding domain thereof.
- Preferred receptor binding domains of the respective proteins are indicated in Table 1 (NH 2 -aa to COOH-aa).
- component (i) is selected from CD95L, TRAIL or TNF ⁇ or a receptor binding domain thereof.
- component (i) comprises the extracellular portion of a TNF cytokine including the receptor binding domain without membrane located domains.
- component (i) of the recombinant fusion protein is selected from human CD95L, particularly amino acids 142-281 or 144-281, or human TRAIL, particularly amino acids 116-281 or 118-281.
- Component (ii) is a flexible linker element located between components (i) and (iii).
- the flexible linker element preferably has a length of 5-20 amino acids, particularly a length of 6, 9, 12, 15 or 18 amino acids.
- the linker element is preferably a glycine/serine linker, i.e. a peptide linker substantially consisting of the amino acids glycine and serine.
- the linker has the amino acid sequence (GSS) n GSG wherein n is 1, 2, 3, 4 or 5.
- Component (iii) is a fibritin trimerization domain, particularly a bacteriophage fibritin trimerization domain, more particularly a fibritin trimerization domain from bacteriophage T4 or related bacteriophages such as T - even bacteriophages or phage RB69 or phage AR1 as shown in Table 2.
- the T4 fibritin trimerization domain is e.g. described in US 6,911,205 or WO 01/19958 , the contents of which is herein incorporated by reference.
- component (iii) comprises the amino acid sequence (G) YIPEAPRDGQ AYVRKDGEWV LLSTFL or a sequence variant having an identity of at least 90% thereto. Examples of preferred sequence variants are shown in Table 3.
- component (iii) has a length of from 20 up to 30 amino acids.
- component (i) is located N-terminally and component (iii) is located C-terminally.
- component (i) is located N-terminally and component (iii) is located C-terminally.
- the invention also refers to embodiments, wherein component (iii) is located N-terminally and component (i) is located C-terminally.
- the fusion protein may additionally comprise an N-terminal signal peptide domain, which allows processing, e.g. extracellular secretion, in a suitable host cell.
- the N-terminal signal peptide domain comprises a protease, e.g. a signal peptidase cleavage site and thus may be removed after or during expression to obtain the mature protein.
- the fusion protein may additionally comprise a C-terminal flexible element, having a length of e.g. 1-50, preferably 10-30 amino acids which may include or connect to a recognition/purification domain, e.g. a FLAG domain, a Streptag domain and/or a poly-His domain.
- a further aspect of the present invention relates to a nucleic acid molecule encoding a fusion protein as described above.
- the nucleic acid molecule may be a DNA molecule, e.g. a double-stranded or single-stranded DNA molecule, or an RNA molecule.
- the nucleic acid molecule may encode the fusion protein or a precursor thereof, e.g. a pro- or pre-proform of the fusion protein which may comprise a signal sequence or other heterologous amino acid portions for secretion or purification which are preferably located at the N- and/or C-terminus of the fusion protein.
- the heterologous amino acid portions may be linked to the first and/or second domain via a protease cleavage site, e.g. a Factor X a , thrombin or IgA protease cleavage site.
- the nucleic acid molecule may be operatively linked to an expression control sequence, .e.g. an expression control sequence which allows expression of the nucleic acid molecule in a desired host cell.
- the nucleic acid molecule may be located on a vector, e.g. a plasmid, a bacteriophage, a viral vector, a chromosal integration vector, etc. Examples of suitable expression control sequences and vectors are described for example by Sambrook et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press , and Ausubel et al. (1989), Current Protocols in Molecular Biology, John Wiley & Sons or more recent editions thereof.
- Suitable host cells include, but are not limited to, prokaryotic cells such as bacteria, e.g. E.coli, eukaryotic host cells such as yeast cells, insect cells, plant cells or animal cells, preferably mammalian cells and, more preferably, human cells.
- prokaryotic cells such as bacteria, e.g. E.coli
- eukaryotic host cells such as yeast cells, insect cells, plant cells or animal cells, preferably mammalian cells and, more preferably, human cells.
- the invention relates to a non-human organism transformed or transfected with a nucleic acid molecule as described above.
- Such transgenic organisms may be generated by known methods of genetic transfer including homologous recombination.
- the fusion protein or the nucleic acid coding therefor may be used for pharmaceutical, diagnostic and/or research applications.
- a further aspect of the present invention relates to a pharmaceutical or diagnostic composition
- a pharmaceutical or diagnostic composition comprising as an active agent at least one fusion protein or a nucleic acid molecule coding therefor as described above.
- the composition may be used in the prophylaxis and/or treatment of disorders selected from proliferative disorders, particularly disorders caused by, associated with and/or accompanied by dysfunction of TNF cytokines, such as tumours, e.g. solid or lymphatic tumours, infectious diseases, inflammatory diseases, metabolic diseases, autoimmune disorders, e.g. rheumatoid and/or arthritic diseases, degenerative diseases, e.g. neurodegenerative diseases such as multiple sclerosis, apoptosis-associated diseases and transplant rejections.
- disorders selected from proliferative disorders, particularly disorders caused by, associated with and/or accompanied by dysfunction of TNF cytokines, such as tumours, e.g. solid or lymphatic tumours, infectious diseases, inflammatory diseases, metabolic diseases, autoimmune disorders, e.g. rheumatoid and/or arthritic diseases, degenerative diseases, e.g. neurodegenerative diseases such as multiple sclerosis, apoptosis-associated diseases and transplant rejections
- composition may be administered as monotherapy or as combination therapy with further medicaments, e.g. cytostatic or chemotherapeutic agents, corticosteroids and/or antibiotics.
- medicaments e.g. cytostatic or chemotherapeutic agents, corticosteroids and/or antibiotics.
- the fusion protein is administered to a subject in need thereof, particularly a human patient, in a sufficient dose for the treatment of the specific conditions by suitable means.
- the fusion protein may be formulated as a pharmaceutical composition together with pharmaceutically acceptable carriers, diluents and/or adjuvants.
- Therapeutic efficacy and toxicity may be determined according to standard protocols.
- the pharmaceutical composition may be administered systemically, e.g. intraperitoneally, intramuscularly or intravenously or locally, e.g. intranasally, subcutaneously or intrathecally. Preferred is intravenous administration.
- the dose of the fusion protein administered will of course be dependent on the subject to be treated, on the subject's weight, the type and severity of the disease, the manner of administration and the judgement of the prescribing physician.
- a daily dose of 0.001 to 100 mg/kg is suitable.
- the resulting protein was designated hs95L-AT4.
- the synthetic gene may be optimized in view of its codon-usage for the expression in suitable host cells, e.g. insect cells or mammalian cells.
- the synthetic gene is cleaved off by means of Cpo-I/Hind-III hydrolysis of the transfer plasmid and cloned into a suitable vector.
- the sequence coding for the C-terminal Streptag-II may be deleted, e.g. by simultaneous hydrolysis with the blunt-end cutters Eco47-III and Oli-I and religation of the vector.
- a stop codon is therefor introduced by the fusion of the restriction enzyme half-sites downstream of the 6xHistag:
- Hek 293T cells grown in DMEM + GlutaMAX (GibCo) supplemented with 10% FBS, 100 units/ml Penicillin and 100 ⁇ g/ml Streptomycin were transiently transfected with a plasmid containing an expression cassette for hs95L-AT4.
- Cell culture supernatant containing recombinant hs95L-AT4 was harvested three days post transfection and clarified by centrifugation at 300 g followed by filtration through a 0.22 ⁇ m sterile filter.
- Streptactin Sepharose was packed to a column (gel bed 1 ml), equilibrated with 15 ml buffer W (100 mM Tris-HCl, 150 mM NaCl pH 8.0) and the cell culture supernatant was applied to the column with a flow rate of 4 ml/min.
- a cellular assay with a Jurkat A3 permanent T-cell line was used to determine the apoptosis inducing activity of different CD95-ligand (CD95L) constructs.
- Jurkat cells were grown in flasks with RPMI 1640-medium + GlutaMAX (GibCo) supplemented with 10% FBS, 100 units/ml Penicillin and 100 ⁇ g/ml Streptomycin. Prior to the assay, 100,000 cells were seeded per well into a 96-well microtiterplate. The addition of different concentrations of CD95L to the wells was followed by a 3 hour incubation at 37°C.
- lysis buffer 250 mM HEPES, 50 mM MgCl 2 , 10 mM EGTA, 5% Triton-x-100, 100 mM DTT, 10 mM AEBSF, pH 7.5
- cleavage of the specific Caspase 3/7 substrate Ac-DEVD-AFC was used to determine the extent of apoptosis.
- Caspase activity correlates with the percentage of apoptotic cells determined morphologically after staining the cells with propidium iodide and Hoechst-33342.
- 20 ⁇ l cell lysate was transferred to a black 96-well microtiterplate.
- 80 ⁇ l buffer containing 50 mM HEPES, 1% Sucrose, 0.1 % CHAPS, 50 ⁇ M Ac-DEVD-AFC, and 25 mM DTT, pH 7.5 the plate was transferred to a Tecan GeniosPro microtiterplate reader and the increase in fluorescence intensity was monitored (excitation wavelength 400 nm, emission wavelength 505 nm).
- Figure 3 demonstrates the induction of caspase activity of SEC fractions of the CD95 ligand hs95L-AT4 in this cellular apoptosis assay.
- the extent of caspase activity is well in line with the hs95L-AT4 content of SEC fractions as shown in Figures 1A and 1 B.
- APG101 a fusion protein comprising the extracellular domain of the human CD95-receptor (the in vivo binding partner of CD95 ligand) with human Fc, antagonizes the apoptosis inducing effect of CD95L.
- CD95L Prior to the addition of CD95L to the Jurkat cells, CD95L at a constant concentration was incubated for 30 minutes at 37°C with different concentrations of APG101.
- An example of the effect of APG101 is shown in Figure 4.
- the CD95 ligand hs95L-AT4 induces caspase activity in a dose dependent manner, an effect which is abolished by APG101.
- gyipeaprdgqayvrkdgewvllstfl (Gly458-Leu485) Natural variants: gi
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06017891A EP1894940A1 (en) | 2006-08-28 | 2006-08-28 | TNF superfamily fusion proteins |
CA2860945A CA2860945C (en) | 2006-08-28 | 2007-08-28 | Fusion proteins comprising trail and fibritin trimerization domain |
JP2009525967A JP5274464B2 (ja) | 2006-08-28 | 2007-08-28 | Tnfスーパーファミリー融合タンパク質 |
PCT/EP2007/007517 WO2008025516A2 (en) | 2006-08-28 | 2007-08-28 | Tnf superfamily fusion proteins |
CA2661599A CA2661599C (en) | 2006-08-28 | 2007-08-28 | Fusion proteins comprising tnf and fibritin trimerization domain |
AT07801940T ATE505481T1 (de) | 2006-08-28 | 2007-08-28 | Fusionsproteine der tnf-superfamilie |
US12/439,486 US8147843B2 (en) | 2006-08-28 | 2007-08-28 | CD95L or trail fusion proteins |
EP07801940A EP2069392B1 (en) | 2006-08-28 | 2007-08-28 | Tnf superfamily fusion proteins |
AU2007291490A AU2007291490A1 (en) | 2006-08-28 | 2007-08-28 | TNF superfamily fusion proteins |
DE602007013920T DE602007013920D1 (de) | 2006-08-28 | 2007-08-28 | Fusionsproteine der tnf-superfamilie |
US13/403,826 US8580273B2 (en) | 2006-08-28 | 2012-02-23 | TNF superfamily member light fusion proteins |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06017891A EP1894940A1 (en) | 2006-08-28 | 2006-08-28 | TNF superfamily fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1894940A1 true EP1894940A1 (en) | 2008-03-05 |
Family
ID=37836940
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06017891A Withdrawn EP1894940A1 (en) | 2006-08-28 | 2006-08-28 | TNF superfamily fusion proteins |
EP07801940A Not-in-force EP2069392B1 (en) | 2006-08-28 | 2007-08-28 | Tnf superfamily fusion proteins |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07801940A Not-in-force EP2069392B1 (en) | 2006-08-28 | 2007-08-28 | Tnf superfamily fusion proteins |
Country Status (8)
Country | Link |
---|---|
US (2) | US8147843B2 (ja) |
EP (2) | EP1894940A1 (ja) |
JP (1) | JP5274464B2 (ja) |
AT (1) | ATE505481T1 (ja) |
AU (1) | AU2007291490A1 (ja) |
CA (2) | CA2860945C (ja) |
DE (1) | DE602007013920D1 (ja) |
WO (1) | WO2008025516A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010006772A2 (en) * | 2008-07-14 | 2010-01-21 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
WO2016090448A1 (pt) * | 2014-12-12 | 2016-06-16 | Fundação Pio Xii | Proteína recombinante; processo de construção da mesma e uso para o tratamento de distúrbios relacionados com a proliferação celular indesejada |
US20200399322A1 (en) * | 2015-11-09 | 2020-12-24 | Curevac Ag | Optimized nucleic acid molecules |
WO2022046634A1 (en) * | 2020-08-24 | 2022-03-03 | Sanofi Pasteur Inc. | Vaccines against sars-cov-2 infections |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2560871T3 (es) | 2007-07-10 | 2016-02-23 | Apogenix Gmbh | Proteínas de fusión de colectina de la superfamilia de TNF |
EP2310409A2 (en) * | 2008-06-17 | 2011-04-20 | Apogenix GmbH | Multimeric tnf receptors |
EP2604693B1 (en) * | 2008-07-21 | 2016-02-24 | Apogenix GmbH | TNFSF single chain molecules |
ES2593049T3 (es) | 2009-01-09 | 2016-12-05 | Apogenix Ag | Proteínas de fusión que forman trímeros |
TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Fc融合蛋白及其用途 |
CA2878427A1 (en) | 2012-07-26 | 2014-01-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
WO2014100913A1 (en) * | 2012-12-24 | 2014-07-03 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
NO2776305T3 (ja) | 2014-04-23 | 2018-01-27 | ||
EP3750918A1 (en) | 2015-01-20 | 2020-12-16 | IGM Biosciences, Inc. | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
EP3076179A1 (en) | 2015-03-30 | 2016-10-05 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Diagnosis and treatment of low grade gliomas |
CA2999116A1 (en) | 2015-09-23 | 2017-03-30 | Apogenix Ag | Anti-cd95l antibody |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
US11357841B2 (en) | 2017-01-06 | 2022-06-14 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
WO2018129332A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
EP3622055A1 (en) | 2017-05-10 | 2020-03-18 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
EP3635097A1 (en) | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
US11578315B2 (en) | 2017-08-11 | 2023-02-14 | The Board Of Trustees Of The University Of Illinois | Truncated guinea pig L-asparaginase variants and methods of use |
SG11202004457XA (en) | 2017-11-17 | 2020-06-29 | Iovance Biotherapeutics Inc | Til expansion from fine needle aspirates and small biopsies |
CA3083118A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
WO2019118873A2 (en) | 2017-12-15 | 2019-06-20 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
EP3737743A1 (en) | 2018-01-08 | 2020-11-18 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
JP2021512962A (ja) | 2018-02-13 | 2021-05-20 | アイオバンス バイオセラピューティクス,インコーポレイテッド | アデノシンa2a受容体アンタゴニストによる腫瘍浸潤性リンパ球(til)の拡大培養並びにtil及びアデノシンa2a受容体アンタゴニストの治療的組み合わせ |
FI3775165T3 (fi) | 2018-03-29 | 2024-07-01 | Iovance Biotherapeutics Inc | Prosesseja kasvaimiin infiltroituvien lymfosyyttien tuottamiseksi ja niiden käyttö immunoterapiassa |
MA52533A (fr) | 2018-04-27 | 2021-03-03 | Iovance Biotherapeutics Inc | Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie |
WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
US20220275043A1 (en) | 2018-07-17 | 2022-09-01 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療 |
BR112021003678A2 (pt) | 2018-09-20 | 2021-05-18 | Iovance Biotherapeutics, Inc. | métodos para criopreservar tecido de tumor, para fabricar, para preparar e para expandir linfócitos infiltrantes de tumor, para tratar um indivíduo com câncer e para tratar câncer para um indivíduo humano, e, fragmento de tumor criopreservado . |
BR112021008266A2 (pt) | 2018-11-05 | 2022-01-04 | Iovance Biotherapeutics Inc | Métodos para expandir linfócitos infiltrantes de tumor em uma população terapêutica de linfócitos infiltrantes de tumor e para tratar um sujeito com câncer, e, população terapêutica de linfócitos infiltrantes de tumor |
JP2022506508A (ja) | 2018-11-05 | 2022-01-17 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Akt経路阻害剤を利用したtilの拡大培養 |
PE20211292A1 (es) | 2018-11-05 | 2021-07-20 | Iovance Biotherapeutics Inc | Procesos para la produccion de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia |
CN112969469A (zh) | 2018-11-05 | 2021-06-15 | 艾欧凡斯生物治疗公司 | 抗pd-1抗体难治性nsclc患者的治疗 |
JP2022514023A (ja) | 2018-12-19 | 2022-02-09 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用 |
JP2022522473A (ja) | 2019-03-01 | 2022-04-19 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 液性腫瘍からの腫瘍浸潤リンパ球の拡大培養及びその治療的使用 |
AU2020256125A1 (en) | 2019-03-29 | 2021-11-18 | Turnstone Biologics Corp. | Ex vivo methods for producing a T cell therapeutic and related compositions and methods |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
EP4048295A1 (en) | 2019-10-25 | 2022-08-31 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2021108727A1 (en) | 2019-11-27 | 2021-06-03 | Myst Therapeutics, Inc. | Method of producing tumor-reactive t cell composition using modulatory agents |
CA3161104A1 (en) | 2019-12-11 | 2021-06-17 | Cecile Chartier-Courtaud | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
JP2023516636A (ja) | 2020-02-27 | 2023-04-20 | ミスト セラピューティクス リミテッド ライアビリティ カンパニー | 腫瘍反応性t細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物 |
TW202208617A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途 |
TW202208616A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 改良之腫瘤反應性t細胞的選擇 |
JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球療法によるnsclc患者の治療 |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
AU2021401302A1 (en) | 2020-12-17 | 2023-07-06 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
EP4262827A1 (en) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
AR126323A1 (es) | 2021-03-05 | 2023-10-04 | Iovance Biotherapeutics Inc | Composiciones para el almacenamiento de tumores y cultivos celulares |
CA3215830A1 (en) | 2021-04-19 | 2022-10-27 | Rafael CUBAS | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
AU2022280269A1 (en) * | 2021-05-27 | 2023-11-30 | Beijing Anxinhuaide Biotech. Co., Ltd | A super-trail molecule comprising two trail trimers |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
EP4404969A1 (en) | 2021-09-24 | 2024-07-31 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
AR127482A1 (es) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1365027A2 (en) * | 2000-05-26 | 2003-11-26 | Mochida Pharmaceutical Co., Ltd. | Fas ligand-fused proteins |
-
2006
- 2006-08-28 EP EP06017891A patent/EP1894940A1/en not_active Withdrawn
-
2007
- 2007-08-28 JP JP2009525967A patent/JP5274464B2/ja not_active Expired - Fee Related
- 2007-08-28 WO PCT/EP2007/007517 patent/WO2008025516A2/en active Application Filing
- 2007-08-28 DE DE602007013920T patent/DE602007013920D1/de active Active
- 2007-08-28 CA CA2860945A patent/CA2860945C/en not_active Expired - Fee Related
- 2007-08-28 US US12/439,486 patent/US8147843B2/en not_active Expired - Fee Related
- 2007-08-28 EP EP07801940A patent/EP2069392B1/en not_active Not-in-force
- 2007-08-28 AT AT07801940T patent/ATE505481T1/de not_active IP Right Cessation
- 2007-08-28 CA CA2661599A patent/CA2661599C/en not_active Expired - Fee Related
- 2007-08-28 AU AU2007291490A patent/AU2007291490A1/en not_active Abandoned
-
2012
- 2012-02-23 US US13/403,826 patent/US8580273B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1365027A2 (en) * | 2000-05-26 | 2003-11-26 | Mochida Pharmaceutical Co., Ltd. | Fas ligand-fused proteins |
Non-Patent Citations (10)
Title |
---|
BELOUSOVA N ET AL: "Genetically targeted adenovirus vector directed to CD40-expressing cells", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 77, no. 21, November 2003 (2003-11-01), pages 11367 - 11377, XP002973705, ISSN: 0022-538X * |
EFIMOV V P ET AL: "BACTERIOPHAGE T4 AS A SURFACE DISPLAY VECTOR", VIRUS GENES, KLUWER ACADEMIC PUBLISHERS, BOSTON, US, vol. 10, no. 2, June 1995 (1995-06-01), pages 173 - 177, XP009070597, ISSN: 0920-8569 * |
FRANK S ET AL: "Stabilization of short collagen-like triple helices by protein engineering", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 308, no. 5, 18 May 2001 (2001-05-18), pages 1081 - 1089, XP004466182, ISSN: 0022-2836 * |
KRASNYKH VICTOR ET AL: "Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 9, May 2001 (2001-05-01), pages 4176 - 4183, XP002202288, ISSN: 0022-538X * |
MEIER S ET AL: "Foldon, The Natural Trimerization Domain of T4 Fibritin, Dissociates into a Monomeric A-state Form containing a Stable beta-Hairpin: Atomic Details of Trimer Dissociation and Local beta-Hairpin Stability from Residual Dipolar Couplings", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 344, no. 4, 3 December 2004 (2004-12-03), pages 1051 - 1069, XP004635848, ISSN: 0022-2836 * |
MIROSHNIKOV K A ET AL: "Engineering trimeric fibrous proteins based on bacteriophage T4 adhesins.", PROTEIN ENGINEERING APR 1998, vol. 11, no. 4, April 1998 (1998-04-01), pages 329 - 332, XP002426507, ISSN: 0269-2139 * |
SHIRAISHI T ET AL: "Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 322, no. 1, 10 September 2004 (2004-09-10), pages 197 - 202, XP004526718, ISSN: 0006-291X * |
SISSOËFF LUDMILLA ET AL: "Stable trimerization of recombinant rabies virus glycoprotein ectodomain is required for interaction with the p75NTR receptor.", THE JOURNAL OF GENERAL VIROLOGY SEP 2005, vol. 86, no. Pt 9, September 2005 (2005-09-01), pages 2543 - 2552, XP002426506, ISSN: 0022-1317 * |
SUN K H ET AL: "Expression, purification, refolding, and characterization of recombinant human soluble-Fas ligand from Escherichia coli", ENZYME AND MICROBIAL TECHNOLOGY, STONEHAM, MA, US, vol. 36, no. 4, 2 March 2005 (2005-03-02), pages 527 - 534, XP004725634, ISSN: 0141-0229 * |
YANG X ET AL: "Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 76, no. 9, May 2002 (2002-05-01), pages 4634 - 4642, XP002321404, ISSN: 0022-538X * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010006772A2 (en) * | 2008-07-14 | 2010-01-21 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
WO2010006772A3 (en) * | 2008-07-14 | 2010-06-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
WO2016090448A1 (pt) * | 2014-12-12 | 2016-06-16 | Fundação Pio Xii | Proteína recombinante; processo de construção da mesma e uso para o tratamento de distúrbios relacionados com a proliferação celular indesejada |
US20200399322A1 (en) * | 2015-11-09 | 2020-12-24 | Curevac Ag | Optimized nucleic acid molecules |
WO2022046634A1 (en) * | 2020-08-24 | 2022-03-03 | Sanofi Pasteur Inc. | Vaccines against sars-cov-2 infections |
Also Published As
Publication number | Publication date |
---|---|
DE602007013920D1 (de) | 2011-05-26 |
WO2008025516A2 (en) | 2008-03-06 |
JP2010501191A (ja) | 2010-01-21 |
WO2008025516A3 (en) | 2008-04-17 |
CA2860945C (en) | 2015-12-29 |
CA2661599A1 (en) | 2008-03-06 |
AU2007291490A1 (en) | 2008-03-06 |
CA2661599C (en) | 2015-06-09 |
US20110027218A1 (en) | 2011-02-03 |
US20120148527A1 (en) | 2012-06-14 |
ATE505481T1 (de) | 2011-04-15 |
JP5274464B2 (ja) | 2013-08-28 |
US8580273B2 (en) | 2013-11-12 |
EP2069392B1 (en) | 2011-04-13 |
CA2860945A1 (en) | 2008-03-06 |
US8147843B2 (en) | 2012-04-03 |
EP2069392A2 (en) | 2009-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1894940A1 (en) | TNF superfamily fusion proteins | |
JP6694409B2 (ja) | Tnfsf一本鎖分子 | |
US10000550B2 (en) | GITRL-collectin fusion proteins and encoding nucleic acids | |
EP2829550A2 (en) | Fusion proteins forming trimers | |
EP2009022A1 (en) | Trimeric death ligands with enhanced activity (tenascin) | |
AU2013203061A1 (en) | TNF superfamily collectin fusion proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
AKX | Designation fees paid | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080906 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8566 |